Groowe / Newsroom / GLUE

⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

GLUE News

Monte Rosa Therapeutics, Inc. Common Stock

Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2025 on the Potential of MRT-6160, a VAV1-directed Molecular Glue Degrader, to Treat Immune-mediated Diseases

globenewswire.com Oct 24, 2025 1:01 PM